Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report

Creative Commons License

İnözü M., Özlü S. G., Özyörük D., KİREMİTCİ S., Çakmakçı S., Avcı B., ...Daha Fazla

Pediatric Hematology Oncology Journal, cilt.7, sa.4, ss.169-172, 2022 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.phoj.2022.08.006
  • Dergi Adı: Pediatric Hematology Oncology Journal
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.169-172
  • Anahtar Kelimeler: Bevacizumab, Eculizumab, Thrombotic microangiopathy
  • Ankara Üniversitesi Adresli: Evet

Özet

Bevacizumab is a monoclonal human antibody that is effective in the treatment of cancers in both adults and children due to inhibition of vascular endothelial growth factor. Throbotic microangiopathy (TMA) is well-known complication of bevacizumab. Herein, we report a case of desmoplastic small round cell tumor in a 17-year-old male presenting with TMA after bevacizumab treatment. Eculizumab was administered as second line agent for treatment of thrombotic microangiopathy and partial remission was achieved. With this case report we would like to emphasize the renal effects of bevacizumab and discuss the role of eculizumab in the treatment of bevacizumab related TMA.